GlassScriptPhysician profile
Alexander M Berry
NPI 1013019439
$2,485.45
in general payments reported to CMS, 2019-2025
26 companies · $376 in 2025
The $376 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $204 · 2021: $258 · 2022: $60.60 · 2023: $315 · 2024: $472 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $300.52 | 2019-2025 | Botox |
| Astellas Pharma US INC | $298.56 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $198.21 | 2019-2020 | |
| Janssen Biotech, INC. | $176.69 | 2019 | |
| Antares Pharma, INC. | $166.51 | 2019-2020 | |
| 180 Medical, INC. | $160.85 | 2019-2025 | Gentlecath, Gentlecath Glide |
| Procept Biorobotics Corporation | $132.52 | 2021 | |
| Myriad Genetic Laboratories, INC. | $125.13 | 2022-2025 | Myrisk, Prolaris |
| Urovant Sciences INC | $125.00 | 2021 | |
| Halozyme INC | $93.40 | 2023 | |
| Sumitomo Pharma America, INC. | $86.68 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $81.90 | 2024-2025 | Axonics, Ams 700 |
| Urogen Pharma, INC. | $78.55 | 2023-2025 | Jelmyto |
| Tolmar Pharmaceuticals, INC. | $67.34 | 2019 | |
| Teleflex LLC | $59.84 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $59.80 | 2019-2024 | |
| Telix Pharmaceuticals | $44.46 | 2023-2024 | Illuccix |
| Janssen Scientific Affairs, LLC | $37.48 | 2019 | |
| Medtronic, INC. | $31.82 | 2025 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $29.30 | 2023 | |
| Olympus America INC. | $28.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.58 | 2024 | |
| Axonics, INC. | $26.48 | 2024 | Bulkamid |
| Ferring Pharmaceuticals INC. | $22.69 | 2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $14.78 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.